CO6300964A2 - Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano - Google Patents

Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano

Info

Publication number
CO6300964A2
CO6300964A2 CO10133385A CO10133385A CO6300964A2 CO 6300964 A2 CO6300964 A2 CO 6300964A2 CO 10133385 A CO10133385 A CO 10133385A CO 10133385 A CO10133385 A CO 10133385A CO 6300964 A2 CO6300964 A2 CO 6300964A2
Authority
CO
Colombia
Prior art keywords
chemotherapeutic agent
antiglipican
antibody
pharmaceutical composition
combination
Prior art date
Application number
CO10133385A
Other languages
English (en)
Inventor
Yasuko Kinoshita
Masamichi Sugimoto
Takahiro Ishiguro
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41135076&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6300964(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/JP2008/002690 external-priority patent/WO2009041062A1/ja
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CO6300964A2 publication Critical patent/CO6300964A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan una composición farmacéutica novedosa para tratar o prevenir carcinoma hepatocelular y un método de tratamiento. Se obtiene una composición farmacéutica para tratar o prevenir cáncer de hígado al combinar un agente .quimioterapéutico con un anticuerpo 3 antiglipicano. También se describe una composición farmacéutica para tratar o prevenir cáncer de hígado que comprende como un ingrediente activo un anticuerpo 3 antiglipicano para uso en combinación con un agente quimioterapéutico, o que comprende como un ingrediente activo un agente quimioterapéutico para uso en combinación con un anticuerpo 3 antiglipicano. La utilización del agente quimioterapéutico y el anticuerpo 3 antiglipicano en combinación proporciona mejores efectos terapéuticos que utilizando solo el agente quimioterapéutico, y mitiga los efectos colaterales que surgen del tratamiento contra el cáncer de hígado tratamiento con el agente quimioterapéutico.
CO10133385A 2008-04-04 2010-10-27 Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano CO6300964A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008098309 2008-04-04
PCT/JP2008/002690 WO2009041062A1 (ja) 2007-09-28 2008-09-26 血漿中動態が改善されたグリピカン３抗体

Publications (1)

Publication Number Publication Date
CO6300964A2 true CO6300964A2 (es) 2011-07-21

Family

ID=41135076

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10133385A CO6300964A2 (es) 2008-04-04 2010-10-27 Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano

Country Status (24)

Country Link
US (1) US20110104157A1 (es)
EP (1) EP2275135A4 (es)
JP (2) JP5306327B2 (es)
KR (1) KR101612139B1 (es)
CN (1) CN102046200B (es)
AR (1) AR071003A1 (es)
AU (1) AU2009233301B2 (es)
BR (1) BRPI0911147A2 (es)
CA (1) CA2720359A1 (es)
CL (1) CL2009000647A1 (es)
CO (1) CO6300964A2 (es)
CR (1) CR11769A (es)
EC (1) ECSP10010589A (es)
HK (1) HK1151734A1 (es)
IL (1) IL208451A0 (es)
MA (1) MA32360B1 (es)
MX (1) MX2010010954A (es)
NZ (1) NZ588913A (es)
PE (1) PE20091655A1 (es)
RU (1) RU2523897C2 (es)
SG (1) SG189754A1 (es)
TW (1) TWI468175B (es)
UA (1) UA103614C2 (es)
WO (1) WO2009122667A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1674111T3 (pl) * 2004-07-09 2011-04-29 Chugai Pharmaceutical Co Ltd Przeciwciała anty-glipikan 3
CA2585196C (en) * 2004-10-26 2015-01-06 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody having modified sugar chain
US20070087005A1 (en) * 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
DK2196541T3 (da) * 2007-09-28 2012-11-26 Chugai Pharmaceutical Co Ltd Anti-glypican-3-antistof med forbedret kinetik i plasmaet
CN104520331B (zh) 2012-06-01 2018-09-07 美国政府(由卫生和人类服务部的部长所代表) 磷脂酰肌醇蛋白聚糖3的高亲和力单克隆抗体及其用途
EP4119947A1 (en) 2012-12-21 2023-01-18 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
TWI693073B (zh) * 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
TWI735410B (zh) 2014-05-08 2021-08-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投予的ｇｐｃ３標的治療劑
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
RU2683020C2 (ru) * 2014-11-11 2019-03-26 Петр Иванович Никитин Субстанция и способ для модуляции активности агента в организме
EP3317274A4 (en) * 2015-06-30 2019-05-08 Eiger Group International, Inc. USE OF CHLOROQUINE AND CLÉMIZOLE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY AND CANCER CONDITIONS
JP7096667B2 (ja) 2015-07-01 2022-07-06 中外製薬株式会社 Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤
US20190046659A1 (en) * 2015-08-03 2019-02-14 Carsgen Therapeutics Ltd Antibody against glypican-3 and application thereof
CA3016552A1 (en) * 2016-03-15 2017-09-21 Genentech, Inc. Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
WO2019059411A1 (en) 2017-09-20 2019-03-28 Chugai Seiyaku Kabushiki Kaisha DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
WO2020017479A1 (ja) * 2018-07-17 2020-01-23 ノイルイミューン・バイオテック株式会社 抗ｇｐｃ３一本鎖抗体を含むｃａｒ
KR102154683B1 (ko) * 2019-11-08 2020-09-11 주식회사 압타머사이언스 글리피칸-3 특이적 변형 압타머 및 이의 용도
KR20220155589A (ko) * 2020-03-18 2022-11-23 주식회사 유틸렉스 Il-18을 분비하는 gpc3 car-t 세포 및 이의 제조 및 사용 방법
KR20220155588A (ko) * 2020-03-18 2022-11-23 주식회사 유틸렉스 Gpc3 car-t 세포 조성물 및 이의 제조 및 사용 방법
WO2022171100A1 (zh) * 2021-02-10 2022-08-18 江苏先声药业有限公司 Gpc3人源化抗体及其应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPS6459878A (en) 1987-08-31 1989-03-07 Matsushita Electric Ind Co Ltd Semiconductor laser protective circuit
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
CA2119930C (en) 1991-09-23 2002-10-01 Hendricus R. J. M. Hoogenboom Production of chimeric antibodies - a combinatorial approach
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
GB9425138D0 (en) * 1994-12-12 1995-02-08 Dynal As Isolation of nucleic acid
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
EP2270150B2 (en) 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
GB0017635D0 (en) * 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
MXPA03002974A (es) 2000-10-06 2004-05-05 Kyowa Hakko Kogyo Kk Celulas que producen composiciones de anticuerpo.
WO2002079255A1 (en) 2001-04-02 2002-10-10 Idec Pharmaceuticals Corporation RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII
JP4281869B2 (ja) * 2001-06-22 2009-06-17 中外製薬株式会社 抗グリピカン３抗体を含む細胞増殖抑制剤
DE60216305T2 (de) * 2001-10-03 2007-07-05 Celator Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zur Abgabe von Arzneimittelkombinationen
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2004022597A1 (ja) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
US20060088899A1 (en) * 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
CA2521414A1 (en) * 2003-04-02 2004-10-21 Celator Pharmaceuticals, Inc. Methods to individualize combination therapy
CA2569277A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
DE102004032634A1 (de) * 2004-07-06 2006-02-16 Sms Demag Ag Verfahren und Einrichtung zum Messen und Regeln der Planheit und/oder der Bandspannungen eines Edelstahlbandes oder einer Edelstahlfolie beim Kaltwalzen in einem Vielwalzengerüst, insbesondere in einem 20-Walzen-Sendizimir-Walzwerk
JP4331227B2 (ja) * 2004-07-09 2009-09-16 中外製薬株式会社 抗グリピカン３抗体
PL1674111T3 (pl) 2004-07-09 2011-04-29 Chugai Pharmaceutical Co Ltd Przeciwciała anty-glipikan 3
KR101300546B1 (ko) * 2004-08-24 2013-09-02 추가이 세이야쿠 가부시키가이샤 항 글리피칸 3 항체를 이용한 어쥬번트 요법
CA2585196C (en) * 2004-10-26 2015-01-06 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody having modified sugar chain
WO2006067847A1 (ja) * 2004-12-22 2006-06-29 Chugai Seiyaku Kabushiki Kaisha フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
US8299252B2 (en) * 2005-08-05 2012-10-30 Chugai Seiyaku Kabushiki Kaisha Pyrazolopyridine and pyrrolopyridine multikinase inhibitors
US20070087005A1 (en) * 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2007053573A2 (en) * 2005-10-31 2007-05-10 Bayer Pharmaceuticals Corporation Treatment of cancer with sorafenib
WO2007059111A2 (en) * 2005-11-14 2007-05-24 Entremed, Inc. Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
EP1982718A4 (en) * 2006-02-09 2010-05-12 Daiichi Sankyo Co Ltd ANTICANCER PHARMACEUTICAL COMPOSITION
WO2007099988A1 (ja) * 2006-02-28 2007-09-07 Kyowa Hakko Kogyo Co., Ltd. α-1,6-フコシルトランスフェラーゼ変異体とその用途
US11046784B2 (en) * 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP3345616A1 (en) * 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
WO2007137170A2 (en) * 2006-05-20 2007-11-29 Seattle Genetics, Inc. Anti-glypican-3 antibody drug conjugates
JP4640675B2 (ja) 2006-06-20 2011-03-02 清水建設株式会社 空調システム
JP4463793B2 (ja) 2006-10-10 2010-05-19 浜松ホトニクス株式会社 光検出装置
SI2178921T1 (sl) * 2007-07-17 2016-05-31 E.R. Squibb & Sons, L.L.C. Monoklonska protitelesa proti glipikan-3
MX369784B (es) * 2007-09-26 2019-11-21 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
DK2196541T3 (da) * 2007-09-28 2012-11-26 Chugai Pharmaceutical Co Ltd Anti-glypican-3-antistof med forbedret kinetik i plasmaet

Also Published As

Publication number Publication date
CL2009000647A1 (es) 2010-06-04
US20110104157A1 (en) 2011-05-05
ECSP10010589A (es) 2010-12-30
MA32360B1 (fr) 2011-06-01
WO2009122667A1 (ja) 2009-10-08
CA2720359A1 (en) 2009-10-08
CN102046200B (zh) 2015-03-25
RU2010145177A (ru) 2012-05-20
AR071003A1 (es) 2010-05-19
JP2011068682A (ja) 2011-04-07
UA103614C2 (uk) 2013-11-11
CN102046200A (zh) 2011-05-04
NZ588913A (en) 2012-10-26
RU2523897C2 (ru) 2014-07-27
PE20091655A1 (es) 2009-11-04
EP2275135A1 (en) 2011-01-19
AU2009233301A1 (en) 2009-10-08
JP5506654B2 (ja) 2014-05-28
BRPI0911147A2 (pt) 2019-09-24
KR20100132060A (ko) 2010-12-16
MX2010010954A (es) 2011-03-24
AU2009233301B2 (en) 2014-01-23
EP2275135A4 (en) 2013-03-06
TWI468175B (zh) 2015-01-11
TW200950804A (en) 2009-12-16
JP5306327B2 (ja) 2013-10-02
KR101612139B1 (ko) 2016-04-12
SG189754A1 (en) 2013-05-31
JPWO2009122667A1 (ja) 2011-07-28
HK1151734A1 (en) 2012-02-10
IL208451A0 (en) 2010-12-30
CR11769A (es) 2011-03-30

Similar Documents

Publication Publication Date Title
CO6300964A2 (es) Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano
CL2023000848A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
CO6670567A2 (es) Métodos de tratamiento contra el cáncer pancreático
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
BR112015016681A8 (pt) uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático
UY31724A (es) " compuestos heterocíclicos novedosos y usos de los mismos"
CO7101246A2 (es) Compuesto de carbamato y preparación y uso de los mismos
MY166014A (en) Combination therapy methods for treating proliferative diseases
CL2008002224A1 (es) Composicion farmaceutica que comprende a) un compuesto seleccionado entre paclitaxel, docetaxel, ispinesib, tiazoloquinolina, entre otro, y b) compuestos inhibidores de aurora quinasa seleccionados entre derivados de imidazopirazina; uso de combinacion y de la composicion para tratar el cancer.
BR112012024349A2 (pt) métodos de tratamento de carcinoma hepatocelular
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
EA201391286A1 (ru) Лечение солидных опухолей
NI200700064A (es) Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3- trifluorometil-fenil)- ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos.
ECSP099792A (es) Nuevos peptidos inhibidores de la replicacion del virus de hepatitis c
PE20121520A1 (es) Formulacion farmaceutica que comprende ranolazina y dronedarona en el tratamiento de fibrilacion auricular
EA201070477A1 (ru) Транс-кломифен для лечения метаболического синдрома
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
PE20121709A1 (es) Una composicion farmaceutica para tratar cancer que comprende tripsinogeno y/o quimotripsinogeno y un agente activo seleccionado a partir de un compuesto de selenio, un compuesto vainilloide y un agente reductor de glicolisis citoplasmica
CL2011000979A1 (es) Compuestos derivados ftalazina 1,4-disustituida; composicion farmaceutica; y su uso en el tratamiento del cancer.
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
AR091739A1 (es) Composiciones y metodos para reducir el riesgo cardiometabolico
PE20141035A1 (es) Composiciones y metodos para tratar el cancer usando el inhibidor de pi3kbeta y el inhibidor de la via de mapk, incluidos los inhibidores de mek y raf
ES2723778T3 (es) Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos
CL2008002758A1 (es) Composicion que comprende al menos un principio activo laxante y al menos un principio activo antiespumante; uso para el tratamiento del estrenimiento.
CL2008003558A1 (es) Composicion farmaceutica que comprende valrubicina y sulfoxido de dimetilo en forma de dosis intravesical, util para tratar cancer a la vejiga.

Legal Events

Date Code Title Description
FG Application granted